GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
W. L. Gore & Associates, Inc. · Decision date Sep 9, 2025
What did the FDA decide?
FDA records P230023/S009 as a supplement to PMA P230023, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 9, 2025.
FDA approval order statement
implementation of an additional primary supplier of radiopaque markers used in the GORE EXCLUDER Iliac Branch Endoprosthesis, Conformable GORE TAG Thoracic Endoprosthesis, GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, and GORE TAG Thoracic Branch Endoprosthesis
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 9, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230023/S009
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QZK
- Decision code
- OK30
- Decision date
- Sep 9, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Endovascular system for treatment of thoracoabdominal and pararenal aortic lesions.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QZK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230023/S009 received
Application receipt date recorded by FDA.
P230023/S009 · FDA decision
30-Day Notice
P230023/S010 · Related supplement
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
P230023/S011 · Related supplement
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE)
P230023/S012 · Related supplement
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
Timeline entries are records held by MedtechLedger for P230023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA supplement | Jan 15, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Apr 9, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Jul 1, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3450 W. Kiltie Ln., Flagstaff, AZ, 86005
Sources and methodology
- Original FDA record: P230023/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

